ArticleBMC gastroenterology2026
Differential expression of the C-Myc gene in intestinal-type and diffuse-type gastric cancer and its clinical significance.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo investigate the differential expression of the c-Myc proto-oncogene in intestinal-type gastric cancer (ITGC), diffuse-type gastric cancer (DTGC), and gastric mucosal intestinal metaplasia (IM), and to assess its clinical significance.
methodsA total of 262 archived paraffin-embedded gastric tissue specimens were obtained from Putuo Hospital, Shanghai University of Traditional Chinese Medicine, collected between January 2016 and December 2024. The specimens included 30 samples of normal gastric mucosa (NM), 180 of IM (subclassified as mild [n = 60], moderate [n = 60], and severe [n = 60]), 30 of ITGC, and 22 of DTGC. C-Myc protein expression was evaluated by immunohistochemistry using the EnVision™ system and categorized as low (< 15% positive cells), moderate (15%-40%), or high (≥ 40%). Statistical analyses were performed using the Mantel-Haenszel trend test, Kruskal-Wallis test, Duncan's multiple comparison test, and chi-square test.
resultsC-Myc expression differed significantly among gastric mucosal lesions (P < 0.001). Moderate IM exhibited higher c-Myc expression than NM, DTGC, and severe IM (P < 0.05). High c-Myc expression was more frequent in ITGC (26.67%) than in DTGC (4.55%), NM, or severe IM (P < 0.05). Among IM subtypes, types I and II IM demonstrated elevated c-Myc expression compared with NM and DTGC (P < 0.05), while type III IM exhibited lower expression levels. Patients with ITGC were significantly older than those in other cohorts (P < 0.05). Female predominance was observed in the NM group, whereas male predominance was observed in the ITGC group.
conclusionC-Myc expression shows stage-specific heterogeneity during gastric carcinogenesis. The significantly higher c-Myc expression in ITGC compared with DTGC supports the molecular basis of the Lauren classification and may aid in the development of targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.